Scholarlink

Background/purpose <p>AHB-137 is a novel antisense oligonucleotide targeting a conserved 3’-terminal region of HBV mRNA. This phase 1a/1b study evaluated the safety, pharmacokinetics (PK), and antiviral activity of AHB-137 in Chinese healthy volunteers (HVs) and chronic hepatitis B (CHB) patients.</p> Methods <p>In Phase 1a, 52 HVs received single ascending doses (75–450&#xa0;mg) or multiple ascending doses (MAD; 150 or 300&#xa0;mg) of AHB-137 or placebo. In Phase 1b, 20 HBeAg-negative, nucleos(t)ide analogue (NA)-suppressed CHB patients with baseline HBsAg 100–1000&#xa0;IU/mL received MAD AHB-137 (150 or 300&#xa0;mg) or placebo (8:2), and 2 patients with baseline HBsAg 1000–3000&#xa0;IU/mL received open-label AHB-137 300&#xa0;mg. MAD comprised 6 subcutaneous doses over 4&#xa0;weeks including loading doses on Days 4 and 11, with safety, PK and virologic follow-up assessments.</p> Results <p>No serious adverse events, deaths or discontinuations occurred. Most treatment-related adverse events were Grade 1–2, including injection site reactions, pyrexia, and asymptomatic lab abnormalities. Transaminase elevations were self-limiting; one Grade 3 ALT elevation in the 300&#xa0;mg CHB cohort coincided with rapid HBsAg loss. PK showed rapid absorption (T<sub>max</sub> 3–5&#xa0;h), dose-proportionality, and a terminal half-life of 128–195&#xa0;h without meaningful accumulation. In CHB patients, 4&#xa0;weeks of AHB-137 induced dose-dependent HBsAg reductions (mean maximum − 1.1 vs. − 2.1 log<sub>10</sub> IU/mL at 150 vs. 300&#xa0;mg), 50.0% of the 300&#xa0;mg cohort achieved ≥ 2 log<sub>10</sub> IU/mL reduction. Preliminary HBsAg loss was observed in a small subset of patients during follow-up.</p> Conclusion <p>AHB-137 demonstrated favorable safety, predictable PK, and dose-dependent HBsAg reductions, including HBsAg loss, supporting its further development for CHB functional cure.</p> Registration number <p>ClinicalTrials.gov. number: NCT06115993. Chinadrugtrials.org.cn. number: CTR20232098.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月23日

查看全文
  • Wen Wang,
  • Jiajia Mai,
  • Jinlin Hou,
  • Zhongyuan Xu,
  • Xian Yu,
  • Hong Ren,
  • Xieer Liang,
  • Yi Yang,
  • Zhihong Liu,
  • Hong Zhang,
  • Shan Zhong,
  • Yilei Wen,
  • Tingting Lu,
  • Haixia Cao,
  • Xiao Qiu,
  • Lidan Wang,
  • Di Zhao,
  • Miao Wang,
  • Chengyong Yang,
  • Guofeng Cheng,
  • Junqi Niu,
  • Yanhua Ding

摘要

Background/purpose

AHB-137 is a novel antisense oligonucleotide targeting a conserved 3’-terminal region of HBV mRNA. This phase 1a/1b study evaluated the safety, pharmacokinetics (PK), and antiviral activity of AHB-137 in Chinese healthy volunteers (HVs) and chronic hepatitis B (CHB) patients.

Methods

In Phase 1a, 52 HVs received single ascending doses (75–450 mg) or multiple ascending doses (MAD; 150 or 300 mg) of AHB-137 or placebo. In Phase 1b, 20 HBeAg-negative, nucleos(t)ide analogue (NA)-suppressed CHB patients with baseline HBsAg 100–1000 IU/mL received MAD AHB-137 (150 or 300 mg) or placebo (8:2), and 2 patients with baseline HBsAg 1000–3000 IU/mL received open-label AHB-137 300 mg. MAD comprised 6 subcutaneous doses over 4 weeks including loading doses on Days 4 and 11, with safety, PK and virologic follow-up assessments.

Results

No serious adverse events, deaths or discontinuations occurred. Most treatment-related adverse events were Grade 1–2, including injection site reactions, pyrexia, and asymptomatic lab abnormalities. Transaminase elevations were self-limiting; one Grade 3 ALT elevation in the 300 mg CHB cohort coincided with rapid HBsAg loss. PK showed rapid absorption (Tmax 3–5 h), dose-proportionality, and a terminal half-life of 128–195 h without meaningful accumulation. In CHB patients, 4 weeks of AHB-137 induced dose-dependent HBsAg reductions (mean maximum − 1.1 vs. − 2.1 log10 IU/mL at 150 vs. 300 mg), 50.0% of the 300 mg cohort achieved ≥ 2 log10 IU/mL reduction. Preliminary HBsAg loss was observed in a small subset of patients during follow-up.

Conclusion

AHB-137 demonstrated favorable safety, predictable PK, and dose-dependent HBsAg reductions, including HBsAg loss, supporting its further development for CHB functional cure.

Registration number

ClinicalTrials.gov. number: NCT06115993. Chinadrugtrials.org.cn. number: CTR20232098.

Graphical abstract